Video

Our team behind the scenes at SXSW | Building a Disease Specific Knowledge Base

In part two of our SXSW series, our team shows how we use AI and machine learning to better understand specific diseases - in this case, Glioblastoma (GBM), the most common and aggressive form of brain cancer.

Given the complexity of a savage disease like GBM, a scientist alone could not read up on all the research that has been done to understand it. At BenevolentAI, we have developed a biomedical knowledge base to contextualise all the relevant information and relationships between diseases, genes, drugs and other important research that has already been published.

Our knowledge graph pulls out all the relevant links to ongoing and completed clinical trials, existing compounds that have been tested against the disease, and the underlying biological connections known to be associated with the disease. Together, these biological facts represent all that is known to be true about a disease today.

Our technology platform helps us understand diseases like GBM by sitting on top of this knowledge base and answering two fundamental questions, i) what do we know about the disease today? and ii) where are the gaps in that knowledge base?


Watch our team demonstrate how algorithms can analyse this knowledge and reason across it to provide scientists and researchers with capabilities beyond human insight.

More Posts

You Might Also Like

Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021
Blog
Joanna Shields speaks at the Global Partnership on Artificial Intelligence
BenevolentAI CEO Joanna Shields opened the final plenary of the Global Partnership on Artificial Intelligence (GPAI) summit with a powerful message on the future of AI.
Dec 11, 2020
Blog
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Dec 11, 2020